- Professor Lees receives Jay Van Andel Award for Outstanding Research in Parkinson’s Disease
- Creating brain cells from skin to study Alzheimer's
- Queen Square authors prominent in Brain collection of classic articles
- Toxic proteins implicated in frontotemporal dementia and motor neurone disease
- Double mutation linked to frontotemporal dementia
- Equation to predict happiness
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia
- Researchers test whether diabetes drug can help Parkinson’s patients
- Acute optic neuritis: a review and proposed protocol
- Hippocampal subfield size predicts the precision of memory recall
- Immune system implicated in dementia development
- UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
- Professor Golay made a Fellow of the ISMRM
- The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
- Professor Rees wins UCLU Student Choice Teaching Award
- New epilepsy treatment offers ‘on demand’ seizure suppression
- Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
- Professor Dolan and Professor Friston elected to EMBO membership
- Vitamin B3 treatment for ataxia shows promise in first human trial
- Teaching Awards 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- UCL and Max Planck Society invest €5m to open world’s first computational psychiatry centre
- Successful launch of new annual leading edge neurology course
- Statins could help control MS
- Professor Hardy awarded Thudichum Medal by Biochemical Society
- Population Screening for vCJD Using a Novel Blood Test
- Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
- New partnership between UCLP brain tumour scientists and Brain Tumour Research
- Professor Hardy awarded Dan David Prize for work on the amyloid gene encoding APP
- NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
- Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
- Major initiative in understanding synaptic basis of neuropsychiatric disease
- Visit to the Berlin School of Mind and Brain
- Institute of Neurology ranked as the world’s top institution for epilepsy research.
- Predicting age at onset in SCA1 : does size matter?
- UCL takes the lead with £8.5m funding for dementia research
- Secretary of State visits leading dementia research projects
- Riboflavin Treatment for Childhood onset Motor Neuron Disease
- Dreading pain can be worse than pain itself
- Different gene expression in male and female brains helps explain differences in brain disorders
- New £20m centre pioneers first-in-man trials for neurodegenerative diseases
- RNA build-up linked to dementia and motor neuron disease
- Researchers estimate one in 2,000 people in the UK carry variant CJD proteins
- Professor Alan Thompson discusses Atlas of MS on Lancet News
- Wellcome Trust Principal Fellowship award to explore neural coding with the tripartite synapse
- Marsden's Book of Movement Disorders wins Neurology first prize at the 2013 BMA Book Awards
- Scientists develop refined diagnostic tool for inherited dementias
- Genetic mutations linked to Parkinson's Disease
- P-glycoprotein over-activity and drug resistance in temporal lobe epilepsy
- New Yale-UCL collaboration in brain aneurysm genetics
- ‘Risky’ stroke prevention procedure may be safe in some patients
- The Michael J. Fox Foundation awards grant for Exenatide research
- Institute Professor leads cross-disciplinary study on use of glucose in detecting cancer.
- Irreversible tissue loss seen within 40 days of spinal cord injury
- From Bedside to Bench in the Institute’s MRC Centre for Neuromuscular Diseases
- Centralising acute stroke services has saved more than 400 lives since 2010
- Rapid Response Innovation Award from The Michael J. Fox Foundation
- Predicting Language Outcome and Recovery After Stroke (PLORAS) project launches new website
- BRC awards over £500k to neuroscience projects
- ABTA Winners
- Diabetes drug could help treat Parkinson's Disease
- Clinical trials are vital tools in stroke research
- New gene identified for Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraparesis
- Teaching Awards 2013
- 14th Annual Queen Square Symposium
- TRACK-HD study identifies early predictors of disease progression in Huntington’s disease
- The Great Brain Experiment: crowdsourcing data on how we think and act
- Psychogenic diseases linked to abnormal brain activity
- Human Brain Project wins major EU funding
- Gene mutation causes familial form of cranio-cervical dystonia
- Professor Ray Dolan awarded prestigious Klaus Joachim Zülch Prize
- Professor Dimitri Kullmann elected Editor of Brain
- IoN News Archive (2012)
- IoN News Archive (2011)
- IoN News Archive (2010)
- IoN News Archive (2009)
- GCH1 gene and Parkinson’s risk
Published: Aug 12, 2014 1:23:13 PM
Published: Feb 20, 2014 6:58:34 PM
Published: Sep 16, 2013 1:37:21 PM
Published: Feb 24, 2014 2:53:53 PM
Published: Jul 16, 2014 5:42:14 PM
Published: Sep 3, 2014 11:00:13 AM
The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
5 June 2014
The new clinical trials unit was established through a £20 million award from the Wolfson Foundation to support research into neurological diseases.
LWENC operates 24hours a day through the partnership between the UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery (NHNN), UCLH at Queen Square.
Facility has been specifically designed to undertake experimental medicine
studies and early phase clinical trials (including first-in-man
studies) aiming at identifying potential disease modifying therapies
in the field of Neurology and Neurodegeneration. These include Alzheimer's
Disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis, Stroke
and Prion disease.
It is very exciting to have reached this milestone. Our funding for the Centre reflects our commitment to supporting this vital area of science. There is a critical need to address the crisis of neurodegenerative disease facing an ageing population.
Paul Ramsbottom, Chief Executive, Wolfson Foundation
Location within the NHNN gives the LWENC unrivalled access to patients across age ranges, ethnicity and disease. The unit brings together the expertise of UCLH’s and UCL’s leading clinicians and scientists across a broad range of neurological and neurodegenerative diseases with renowned international collaborators and industry partners - the focus is on experimental medicine and early phase trials in patients and healthy volunteers.
We have exciting years ahead of us. Our mission is to provide world class clinical and governance expertise and infrastructure to expedite translational research and the early evaluation of novel treatments for neurodegenerative diseases. I, along with the rest of the LWENC team, am looking forward to this exciting venture at Queen Square.
Dr Vincenzo Libri, Head of the LWENC Clinical Facility
Strong working relationships are established between the LWENC and key service supports within UCLH and UCL, including the Joint Research Office, Pharmacy, Imaging and the Neuroscience Laboratories for blood and CSF biomarkers. Since it opened, the Centre has adopted more than 20 clinical trials in patients.
The Centre has three inpatient rooms and an infusion suite with three recliner chairs and has been designed to provide close monitoring in a relaxed and comfortable environment.
It also houses a consulting room and a laboratory for processing and storage of research samples.
The Centre is staffed with an experienced medical and nursing team who are fully trained in research governance and regulatory affairs and can provide administrative support for developing protocols and completing regulatory documents and contracts. All members of staff are GCP trained and hold different levels of training in medical emergencies, including Advanced Life Support (ALS) as standard for doctors and Immediate Life Support (ILS) as standard for nurses.
Immediate access ensures that patient safety is at the core of running successful clinical trials with safe drug administration and highly efficient monitoring and management of emerging clinical abnormalities and/or adverse reactions.
Edwina Saunders, Senior Research Nurse
The LWENC is located on the Ground Floor of the Albany Wing at the NHNN, giving immediate access to ICU and a 24-hour emergency response team who can arrive at the Centre within two minutes of an emergency. This, coupled with the experienced and fully trained in-house clinical team, ensures the successful set up of safe drug administration, advanced sampling and highly efficient monitoring/management of emerging clinical abnormalities and/or adverse reactions to study drugs.
Contact Details for queries:
- Manoj Maistry-Administrator: Manoj.email@example.com 0203448431
- Marivic Ricamara-Acting Lead Nurse: Marivic.firstname.lastname@example.org 07957479199
- Edwina Saunders-Senior Research Nurse: Edwina.email@example.com 07956727692
Page last modified on 14 may 14 15:12